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The cleaved peptide of PAR1 is a more potent
stimulant of platelet–endothelial cell adhesion
than is thrombin
R. Brannon Claytor, MD,a Alan D. Michelson, MD,b Jian-Ming Li, MD,a A. L. Frelinger III, PhD,b
Michael J. Rohrer, MD,a Charles S. C. Garnette, MD,a Marc R. Barnard, MS,b Lori A. Krueger, BS,b
and Mark I. Furman, MD,b Worcester, Mass
Purpose: Platelet-endothelial cell adhesion is an important pathologic response to vessel injury or inflammation. On
binding to its endothelial or platelet G protein–linked seven-transmembrane domain receptor, protease-activated
receptor-1 (PAR1), thrombin releases a 41-amino acid peptide (TR1-41). We examined the effect of TR1-41 on platelet
activation and on platelet–endothelial cell adhesion.
Methods: A monolayer of confluent human saphenous vein endothelial cells was incubated with washed human platelets.
Platelets were stimulated with either TR1-41, TR21-41, scrambled TR1-41, adenosine diphosphate (ADP)–epinephrine
(EPI), thrombin, or thrombin receptor activating peptide (TRAP). Platelet activation was identified with flow cytometry.
The magnitude of platelet-endothelial cell adhesion was determined with a laser scanning cytometer that scanned the
monolayer of endothelial cells and identified fluorescently bound platelets.
Results: Maximal thrombin stimulation (0.1 U/mL) induced a threefold increase in platelets bound to endothelial cells
compared with buffer alone. Stimulation with TR1-41 (20 mmol/L) tripled the number of platelets bound to endothelial
cells compared with thrombin. Scrambled sequence of TR1-41 (20 mmol/L) and TR21-41 (20 mmol/L), neither of which
induces platelet activation, had minimal effect on platelet adhesion. Both TRAP (20 mmol/L) and ADP-EPI (20
mmol/L) induced less platelet–endothelial cell adhesion than did thrombin. TR1-41-induced platelet–endothelial cell
adhesion was partially blocked by glycoprotein (GP)IIb-IIIa–specific monoclonal antibody, 10E5 (10 mg/mL).
Conclusions: TR1-41, the cleaved peptide of PAR1, is a more potent stimulant of platelet–endothelial cell adhesion than
is thrombin, TRAP, or ADP-EPI, and this adhesion is at least in part mediated by the platelet GPIIb-IIIa receptor. (J
Vasc Surg 2003;37:440-5.)
A number of thrombin binding sites have been identi-
fied on human platelets, including protease-actived recep-
tor-1 (PAR1), a G protein–coupled, seven transmembrane
domain receptor,1 PAR4,2 and glycoprotein (GP) Ib.3
While less is know about the action of GPIb, cleavage of
PAR1 by thrombin is well established.1 PAR1 is proteolyti-
cally cleaved by thrombin between residues Arg-41 and
Ser-42, releasing the N-terminal polypeptide and exposing
the tethered ligand1-4 (Fig 1). Synthetic peptides of the
tethered ligand, referred to as thrombin receptor activating
peptide (TRAP), exhibit PAR1 activating properties inde-
pendent of thrombin stimulation.1 Recently a 41-residue
polypeptide analogous to that released from PAR1
(TR1-41) has been shown to be a strong platelet agonist.
5
In normal physiologic states, circulating platelets do
not adhere to intact endothelium either in vivo or in
vitro.6,7 Platelet–endothelial cell adhesion is an important
pathologic response to vessel injury and inflammation.
Platelets can adhere to endothelial cells infected by a virus8
or stimulated by thrombin,7,9,10 and platelet–endothelial
cell adhesion has been documented in patients with acute
myocardial infarction during reperfusion.11 Thrombin-in-
duced adhesion of platelets to endothelial cells is mediated,
at least in part, by platelet GPIIb-IIIa (integrin
IIb3).
10,12 GPIIb-IIIa is constitutively expressed on the
platelet surface, and on activation avidly binds to fibrino-
gen, fibronectin, vitronectin, or von Willebrand factor.13
Activation of the GPIIb-IIIa complex is partially responsi-
ble for platelet-platelet aggregation and platelet–endothe-
lial cell adherence.10,12,13 While thrombin-induced adhe-
sion and TR1-41-induced platelet activation are well
documented,5,10,12 nothing is known about the adhesive
response induced by this released amino terminal polypep-
tide. We examined the adhesion of platelets to human
saphenous vein endothelial cells after stimulation with
TR1-41.
METHODS
Endothelial cell preparation. Human saphenous
vein endothelial cells were harvested and cultured as previ-
ously described.14 Endothelial cells (passage 9 to 11) were
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seeded in single cell layer onto 18 mm diameter sterilized
glass cover slips placed at the bottom of 12-well polystyrene
plates. Cells were cultured at 37° C in a humidified 95%
air/5% carbon dioxide incubator in Dulbecco’s modified
Eagle’s medium (DMEM) supplemented with 10% fetal
bovine serum (Gibco, Grand Island, NY), 50 U/mL of
penicillin, and 50 mg/mL of streptomycin (Sigma, Gaith-
ersburg, Md) for 2 days. The medium was then replaced
with 5% fetal bovine serum in DMEM, and cells were
allowed to grow until confluent, and were used on days 7 to
10. On the day of the adhesion experiments, confluent
endothelial cells were washed twice with Dulbecco’s phos-
phate-buffered saline solution at 37° C and then main-
tained in modified HEPES (N-2-hydroxyethylpiperazine-
N-2-ethanesulfonic acid)–Tyrode’s buffer (137 mmol/L
of sodium chloride, 2.8 mmol/L of potassium chloride, 1
mmol/L of magnesium chloride, 12 mmol/L of sodium
bicarbonate, 0.4 mmol/L of HEPES, 5.5 mmol/L of
glucose, 0.35% bovine serum albumin), pH 7.4, during the
platelet preparation procedure.
Platelet preparation. Platelets were prepared on the
day of the experiment. Fifteen milliliters of blood was
drawn by peripheral venipuncture from healthy adult vol-
unteers, as approved by the Committee for the Protection
of Human Subjects in Research at University of Massachu-
setts Memorial Health Care. Only one volunteer was
needed to obtain a sufficient number of platelets for each
experiment. Subjects had not ingested aspirin or other
anti-platelet drugs during the previous 10 days. The blood
was drawn directly into a 5 mL Vacutainer (Becton Dick-
inson, Rutherford, NJ) containing 0.5 mL of a 0.129M
sodium citrate solution and centrifuged at 150g for 10
minutes at 22° C. Platelet-rich plasma was then removed
and incubated with Biotin-X-NHS (Calbiochem, La Jolla,
Calif) at a final concentration of 0.4 mg/mL. Biotin-PRP
solution was diluted to total volume of 15 mL with citrate
wash buffer (128 mmol/L of sodium chloride, 4.3
mmol/L of sodium biphosphate, 7.5 mmol/L of
Na2HPO4, 4.8 mmol/L of sodium citrate, 2.4 mmol/L of
citric acid, 11 mmol/L glucose, 0.35% bovine serum albu-
min with 50 ng/mL of prostaglandin E1 [Sigma]), pH 6.5,
and centrifuged at 1200g for 10 minutes at 22° C. The
pellet was resuspended in citrate wash buffer, centrifuged,
then resuspended in HEPES-Tyrode’s buffer to a concen-
tration of 75,000 platelets/mL. Platelet counts were per-
formed with an automated particle counter (ZBI; Coulter
Electronics, Miami, Fla).
Synthetic peptide synthesis. Twenty millimoles per
liter of TR1-41 (MGPRRLLLVAACFSLCGPLLSARTR-
ARRPESKATNATLDPR), 20 mmol/L of TR1-41 scram-
Fig 1. A, The thrombin receptor, protease-activated receptor 1, is proteolytically cleaved between residues Arg-41
and Ser-42. B, The cleaved peptide is released, and the tethered ligand binds to and activates the receptor on the
platelet.
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bled sequence (LRTNASLLVPFLTARAKSSGTREAAD-
PPRLMCLRPLARRCG), and 20 mmol/L of TR21-41
(SARTRARRPESKATNATLDPR) were synthesized in
the core peptide facility of the University of Massachusetts
Medical Center as previously described.5
Determination of maximal concentration of ago-
nist. To directly compare the effect of each agonist on
platelet endothelial cell adhesion, we used concentrations
that induce maximal platelet activation for each agonist.
Concentration-response curves identified 20 mmol/L of
TR1-41 as the concentration at which maximal platelet–
endothelial cell adhesion was achieved (data not shown).
Similar concentrations of partial sequence and scrambled
sequence of the cleaved peptide were used as controls.
Platelet activation. To induce activation, washed
platelets were incubated for 10 minutes at 22° C in 15 mL
of Falcon polypropylene conical tubes (Becton Dickinson)
with either 0.1 U/mL of human -thrombin isolated from
human plasma (Calbiochem), 20 mol/L of TRAP (Cal-
biochem), 20 mol/L of ADP-EPI (Bio/Data, Horsham,
Pa), 20mol/L of TR1-41, 20mol/L of TR1-41 scrambled
sequence, and 20 mol/L of TR21-41 (University of Mas-
sachusetts Core Peptide Facility, Worcester, Mass). Sepa-
rate aliquots of washed platelets were preincubated with a
blocking antibody to the GPIIb-IIIa complex, 10E5 (gen-
erous gift of Dr. Barry S. Coller, Rockefeller University,
New York). A final concentration of 10 mg/mL of 10E5
was incubated for 20 minutes at 22° C with washed plate-
lets before incubation with thrombin. All samples were
compared with 10 mg/mL of mouse immunoglobulin G
nonspecific antibody (Boehringer Mannheim, Indianapo-
lis, Ind).
Platelet flow cytometry. Platelets were prepared as
described above and tested with the following method in
parallel with the endothelial cell–platelet binding assay.
Flow cytometric analysis is well described in prior publica-
tions.5 In brief, 5 mL of the final platelet preparation was
diluted 1:10 in HEPES-Tyrode’s buffer containing a com-
bination of anti-CD41-PE (DAKO Corp, Carpinteria,
Calif) and either anti P-selectin–fluorescein isothiocyanate
(FITC) (PB1.3; Cytel Corp, San Diego, Calif), anti-bound
fibrinogen-FITC (Clone F26; Dr H. Gralnick, NHLBI,
Bethesda, Md), or anti-activated GPIIb-IIIa–FITC
(PAC-1; Becton Dickinson). This mixture contained either
buffer alone (unactivated), 0.1 U/mL of human -throm-
bin, 20 mmol/L of ADP plus 20 mmol/L of epinephrine,
20 mmol/L of TRAP, 20 mmol/L of TR1-41, 20 mmol/L
of TR21-41, or 20 mmol/L of scrambled TR1-41. After
15-minute incubation, 0.5 mL of phosphate-buffered sa-
line solution plus 1% formaldehyde was added, and the
samples were stored at 4° C until analyzed. Flow cytometry
was performed with a FACSCalibur (Becton Dickinson),
which was calibrated daily with Rainbow Calibration Parti-
cles (RCP-30-5; Spherotech Inc, Libertyville, Ill). The data
are presented as linear mean fluorescence representing rel-
ative antibody binding.
Platelet–endothelial cell adhesion. After activation
of the platelets, HEPES-Tyrode’s buffer was gently aspi-
rated from the endothelial cells, and 300 mL of 75,000
platelets/mL was gently aliquoted onto the endothelial cell
monolayer of each well. All samples were run in triplicate.
Platelet–endothelial cells were incubated at 22° C for 30
minutes, then fixed with 1% formaldehyde in phosphate-
buffered saline solution (final concentration). Fifteen min-
utes before fixation, phycoerythrin-streptavidin, 16.7
mg/mL final concentration, which binds with high affinity
to biotin, was added to the wells. After 30 minutes of
fixation, individual glass cover slips were gently removed
from wells and rinsed three times with Dulbecco’s PBS,
inverted, and placed on glass slides. The edges were then
sealed with Cytoseal 280 mounting medium (Stephens
Scientific, Kalamazoo, Mich) to maintain cells in an aque-
ous environment. Slides were stored in the dark at 4° C and
analyzed within 24 hours.
Quantifying bound platelets. Slides were analyzed
to quantify platelets binding to endothelial cells with a laser
scanning cytometer (LSC) (Compucyte Corp, Cambridge,
Mass). The LSC is controlled by a computer, which auto-
mates scanning and processes data from the sensors in the
optics-electronics unit.15 Identification of platelets was be-
gun with excitation of the phycoerythrin bound to the
platelets with a 488 nm argon ion laser operated at 5 mW.
Laser-excited fluorescence emitted from fluorochromed
platelets was measured at multiple wavelengths. Single
platelets were visually identified, and the corresponding
LSC image was adjusted to achieve the optimal signal-to-
noise ratio. The phycoerythrin sensor (575 nm bandpass
filter) provided optimal detection of the labeled platelets,
and the FITC sensor (525 nm bandpass filter) provided
optimal detection of background autofluorescence from
endothelial cells. All detected events were plotted, and
autofluorescent events were excluded from analysis to pro-
vide an accurate representation of only platelets. A standard
area of 4  4 mm of the endothelial cell monolayer was
scanned for each slide. The total number of platelet events
recorded indicated the number of platelets bound per 16
mm2.
RESULTS
Functional assays of platelet activation. After plate-
let activation with the various agonists the platelets were
separated into portions being analyzed with flow cytometry
for platelet activation analysis and portions being incubated
with endothelial cells for adhesion analysis. The monoclo-
nal antibody PB1.3 binds to P-selectin, which is released
after activation from alpha granules of platelets. The effect
of a mild platelet agonist such as ADP-EPI (20 mmol/L for
10 minutes) resulted in a moderate increase in platelet
surface P-selectin. However, thrombin, a strong platelet
agonist, induced a large increase in platelet surface P-
selectin. TRAP induced an equally large P-selectin re-
sponse. The cleaved peptide TR1-41 stimulated platelets to
express significant quantities of P-selectin, whereas the
scrambled sequence and TR21-41 had similar P-selectin
expression to that of buffer alone (Fig 2).
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As a strong agonist, thrombin induces a large increase
in activated GPIIb-IIIa, as indicated by increased PAC-1
antibody binding (Fig 3). The cleaved peptide TR1-41
induces a response similar to that of ADP-EPI and TRAP,
while neither the scrambled nor the partial sequence of the
cleaved peptide TR21-41 produces any change in GIIb-IIIa
expression over that of buffer alone. The monoclonal anti-
body F26 adheres to platelet-bound fibrinogen. Platelets
activated by thrombin and TRAP demonstrate a substantial
increase in F26 binding over those incubated with buffer
alone (Fig 4). However, platelets incubated with the
cleaved peptide TR1-41 (mean fluorescence, 1475.3 127)
induce a 10-fold increase in surface-bound fibrinogen over
that of thrombin (mean fluorescence, 104.5 9), whereas
the partial and scrambled sequences of the cleaved peptide
have an effect similar to that of buffer alone (Fig 4).
Functional assay of platelet–endothelial cell adhe-
sion. Platelet–endothelial cell adhesion was quantified by
LSC detection of fluorescent platelets bound to an intact
monolayer of human saphenous vein endothelial cells per
16 mm2 area (Fig 5). Platelets incubated with buffer alone
exhibited baseline binding to the endothelial cell mono-
layer of 1597  849 (mean  SEM, n  4). Nearly three
times as many platelets adhered to endothelial cells when
stimulated by thrombin (4023  1789, n  4) compared
with buffer alone (P .05, Student t test). Compared with
thrombin, TR1-41-stimulated platetets more than tripled
the number of platelets bound to endothelial cells
(14,460  1477; P  .0005) (Figs 5 and 6). ADP-EPI
induced less adhesion than did thrombin (3125  1312),
as did TRAP (3231  227). Compared with buffer alone,
scrambled sequence of TR1-41 and TR21-41, which are not
agonists for platelet activation,5 had no significant effects
on platelet–endothelial cell adhesion: 2636  1309 and
2485  2319, respectively (Fig 6).
The GPIIb-IIIa blocking antibody 10E5 reduces plate-
let–endothelial cell adhesion induced by thrombin.10 Pre-
incubating platelets with the monoclonal antibody 10E5
reduced thrombin-induced and TR1-41-induced platelet–
endothelial cell adhesion by 71.6%  14.1% and 55.5% 
18.4%, respectively (mean  SEM, n  6) (Fig 7).
DISCUSSION
Thrombin cleaves the G protein–linked seven trans-
membrane receptor PAR1 between residues Arg-41 and
Ser-42, which releases a 41-residue peptide, TR1-41.
1 The
only known function of TR1-41 is as a strong platelet
agonist.5 The present study demonstrates a new function
for TR1-41 as a potent stimulus for platelet–endothelial cell
adhesion. Thrombin is a strong stimulant for platelet–
endothelial cell adhesion9,10; however, we demonstrate
that TR1-41 is a more potent agonist than thrombin for
platelet–endothelial cell adhesion.
Thrombin-induced platelet–endothelial cell adhesion
is at least partially mediated by GPIIb-IIIa, inasmuch as
preincubation with 10E5, a GPIIb-IIIa blocking monoclo-
nal antibody, inhibited platelet–endothelial cell binding.10
Fig 2. Effect of agonists on platelet surface P-selectin, reflecting
alpha degranulation, as detected with flow cytometric analysis of
fluorescently labeled PB1.3 antibody. Concentrations of agonists:
0.1 U/mL of human -thrombin, 20 mol/L of TRAP, 20
mol/L of ADP-EPI, 20 mol/L of TR1-41, 20 mol/L of
TR1-41 scrambled sequence, and 20 mol/L of TR21-41. Data
represent mean  SEM, n  4. *P  .05 compared with buffer.
Fig 3. Effect of agonists on activated GPIIb-IIIa on the platelet
surface as detected with flow cytometric analysis of fluorescently
labeled PAC-1 antibody. Data represent mean  SEM, n  4.
*P  .05 compared with buffer.
Fig 4. Effect of agonists on bound fibrinogen to platelets as
detected with flow cytometric analysis of fluorescently labeled F26
antibody. TR1-41 induces a nearly 10-fold increase in bound fibrin-
ogen compared with thrombin-activated platelets. Data represent
mean SEM, n 4. *P .05 compared with buffer. **P .0005
compared with buffer.
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TR1-41-induced platelet–endothelial cell adhesion is also at
least partially mediated by platelet GPIIb-IIIa, because this
adhesion can be partially inhibited by 10E5. Fibrinogen
bridging between platelet GPIIb-IIIa and endothelial cell
intercellular adhesion molecule–1 or integrin v3 is one
reported mechanism of thrombin-induced platelet–endo-
thelial cell adhesion.12 Therefore the mechanism of the
greater TR1-41-induced platelet–endothelial cell adhesion,
compared with thrombin-induced platelet–endothelial cell
adhesion, may be the greater TR1-41-induced fibrinogen
binding to activated platelet GPIIb-IIIa.5
In addition to fibrinogen, other plasma adhesive glyco-
proteins, eg, victronectin and thrombospondin, bind the
vitronectin receptor (v3) on the luminal surface of the
endothelium. Activation of endothelial cells results in trans-
location of the large intracellular stores of v3 to the
membrane surface.16 Gawaz et al.17 demonstrated that
thrombin stimulation of endothelial cells increased the
luminal expression of both subunits of the vitronectin
receptor by 40%. If TR1-41 activates endothelial cells in a
manner consistent with that of thrombin, TR1-41 may also
Fig 5. Representative samples of endothelial cells incubated with
buffer alone (A), 0.1 U/mL of thrombin (B), or 20 mol/L of
TR1-41 (C). In these laser scanned images with forward scatter and
fluorescence, fluorescent platelets are indicated by red, green, and
blue concentric circles. Each image is approximately 350 500 .
Fig 6. Number of platelets adherent to endothelial cells as deter-
mined with laser scanning cytometry. Incubation of platelets with
agonists was compared with incubation of platelets with buffer
alone. Only thrombin and TR1-41 significantly increased the num-
ber of adherent platelets. Platelets activated by TR1-41 were three
times more adherent than platelets activated by thrombin. Data
respresent mean  SEM, n  4. *P  .05 compared with buffer.
**P  .0005 compared with buffer.
Fig 7. Platelet adhesion to endothelial cells incubated with either
thrombin or TR1-41 was normalized at 100% binding for subse-
quent comparison with platelets preincubated with 10E5 (GPIIb-
IIIa blocking) antibody before incubation with endothelial cells.
Preincubation with 10E5 reduced thrombin and induced binding
to endothelial cells by 71.6% 14.1% compared with no blocking
antibody. Platelets stimulated by TR1-41 reduced binding by
55.5%  18.4% compared with no blocking antibody when prein-
cubated with 10E5. TR1-41-induced adhesion is significantly
reduced by preincubation with 10E5, but not so significantly as for
thrombin adhesion. Data represent mean  SEM, n  4.
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increase expression of v3 on luminal surfaces. Future
experiments are necessary to address this possiblity.
The more potent effect of TR1-41 on platelet–endothe-
lial cell adhesion compared with that of thrombin is a new
finding. One reason for this marked increase in adhesion
may be increased release of fibrinogen from the platelets
when stimulated by TR1-41. The reason for the large release
of fibrinogen is unknown; however, its presence was con-
firmed by flow cytometric data in our experiment and by
Furman et al.5 Could the peptide TR1-41 in microenviron-
ments have a synergistic effect with that of thrombin? Does
the peptide undergo any further changes after cleavage?
How does the peptide bind to the platelet? These are some
of many questions that warrant further investigation.
Another explanation for the increased binding of plate-
lets to endothelial cells may be brought about by the
TR1-41 effect on the endothelial cells directly. The agonists
were incubated first with the platelets and then were added
to the confluent endothelial cells. The effect of the agonists
on the endothelial cells was not measured separately, as was
done for the platelets. This was done to simplify the exper-
iment, but the increased adhesion induced by TR1-41 may
have been the result of an undetected change in the endo-
thelial cells that may be responsible for the increased adhe-
sion. The potential for clinical intervention, based on the
influence of TR1-41 on platelet activation and subsequent
platelet–endothelial cell adhesion, may be substantial. Cur-
rently GPIIb-IIIa blockers such as abciximab are being
used clinically with good results to prevent platelet aggre-
gation after cardiac stent placement.18 Inhibiting the acti-
vated GPIIb-IIIa receptor binding not only decreases
platelet aggregation, but it may also prevent in vivo platele-
t–endothelial cell adhesion. These drugs have been exten-
sively used in patients undergoing coronary angioplasty
with placement of a stent, and similar results may be seen
with stent placement in peripheral vessels, especially smaller
vessels.
TR1-41 induced a threefold increase in platelet–endo-
thelial cell adhesion over that of thrombin and a 10-fold
increase in levels of bound fibrinogen on the platelet surface
over that of thrombin. An antibody, or a blocking peptide,
directed at the cleaved peptide TR1-41 could potentially
provide a beneficial effect in platelets.
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